Uploaded January 2026 | Updated September 2026, 1 week ago
Oxford Nanopore is back in growth mode.
After fears over lost US government contracts rattled investors last year, the gene-sequencing company has delivered a strong trading update. Revenue rose 24% in constant currency, growth was broad-based across regions, and demand from clinical and biotech customers surged. Julian Hoffman breaks down what’s driving the recovery, why cash generation has improved, and what investors should watch ahead of full-year results.
Read more here:
investorschronicle.co.uk/content/74ce23cd-aafc-4d26-ba29-b0cc97dcae15?utm_source=social&utm_medium=youtube&utm_campaign=editorial&utm_content=skip
#OxfordNanopore #BiotechStocks #GeneSequencing #UKStocks #TradingUpdate #Investing #finance #personalfinance #investments #business
Listen to our podcasts: investorschronicle.co.uk/podcasts/?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Subscribe to Investors' Chronicle: investorschronicle.co.uk/product-matrix?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Our award-winning expert writers research hundreds of companies and funds suitable for all risk appetites, to provide clear, independent recommendations for individual investors who want to make their money grow and outline how to make the most of different types of investment vehicles at all stages of your life.
Follow The Companies and Markets Show on @YouTube: youtube.com/playlist?list=PLnrcXTQl38frCLdb4HDxepjhvod-gN662
Follow Lee and the IC: youtube.com/playlist?list=PLnrcXTQl38fqB-A5bJJ-GtFjm3Q9S9Xnx
Listen to our interviews here: youtube.com/playlist?list=PLnrcXTQl38fo1Oio19rTsLt9fD2s4hKst
Follow us on LinkedIn: linkedin.com/showcase/financial-times---investors-chronicle
Follow us on Instagram: instagram.com/investorschronicle/?hl=en
Get the latest investing updates on WhatsApp: whatsapp.com/channel/0029VaD6zjW9WtBxc0gFG13F
Oxford Nanopore is back in growth mode.
After fears over lost US government contracts rattled investors last year, the gene-sequencing company has delivered a strong trading update. Revenue rose 24% in constant currency, growth was broad-based across regions, and demand from clinical and biotech customers surged. Julian Hoffman breaks down what’s driving the recovery, why cash generation has improved, and what investors should watch ahead of full-year results.
Read more here:
investorschronicle.co.uk/content/74ce23cd-aafc-4d26-ba29-b0cc97dcae15?utm_source=social&utm_medium=youtube&utm_campaign=editorial&utm_content=skip
#OxfordNanopore #BiotechStocks #GeneSequencing #UKStocks #TradingUpdate #Investing #finance #personalfinance #investments #business
Listen to our podcasts: investorschronicle.co.uk/podcasts/?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Subscribe to Investors' Chronicle: investorschronicle.co.uk/product-matrix?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Our award-winning expert writers research hundreds of companies and funds suitable for all risk appetites, to provide clear, independent recommendations for individual investors who want to make their money grow and outline how to make the most of different types of investment vehicles at all stages of your life.
Follow The Companies and Markets Show on @YouTube: youtube.com/playlist?list=PLnrcXTQl38frCLdb4HDxepjhvod-gN662
Follow Lee and the IC: youtube.com/playlist?list=PLnrcXTQl38fqB-A5bJJ-GtFjm3Q9S9Xnx
Listen to our interviews here: youtube.com/playlist?list=PLnrcXTQl38fo1Oio19rTsLt9fD2s4hKst
Follow us on LinkedIn: linkedin.com/showcase/financial-times---investors-chronicle
Follow us on Instagram: instagram.com/investorschronicle/?hl=en
Get the latest investing updates on WhatsApp: whatsapp.com/channel/0029VaD6zjW9WtBxc0gFG13F
